Literature DB >> 17981617

Human antibody libraries: a race to engineer and explore a larger diversity.

Philippe Mondon1, Olivier Dubreuil, Khalil Bouayadi, Hakim Kharrat.   

Abstract

Several recombinant antibody libraries associated with different screening technologies have been generated since the first steps of antibody engineering 15 years ago, in order to isolate human monoclonal antibodies. In this race to isolate antibody with virtually any specificity, innovative strategies have been developed to clone natural antibody repertoires or to increase library diversity beyond the scope of the immune system. After the in vitro transfer of the natural diversity, the second generation of partly or completely man-designed libraries was based on the available structural data of the antibody binding. Efficient selection strategies have proven critical in exploiting the potential of a library's diversity. The development and improvement of screening methods such as phage display, yeast display, ribosome display and robotic platforms have provided innovative tools to efficiently screen and sort out the desired binding specificities of billions of antibodies. Efforts to improve diversity exploration have been mainly focused on screening conditions of display techniques and the new emerging techniques. Here we review some of these prominent approaches in the field of human recombinant antibody libraries.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17981617     DOI: 10.2741/2749

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  10 in total

1.  Functional selection of hepatitis C virus envelope E2-binding Peptide ligands by using ribosome display.

Authors:  Fang Chen; Yinglan Zhao; Min Liu; Dongqing Li; Hongyan Wu; Haidan Chen; Yongzhe Zhu; Fengling Luo; Jin Zhong; Yidan Zhou; Zhongtian Qi; Xiao-Lian Zhang
Journal:  Antimicrob Agents Chemother       Date:  2010-05-17       Impact factor: 5.191

2.  A One-Step Process for the Construction of Phage Display scFv and VHH Libraries.

Authors:  Carolin Sellmann; Lukas Pekar; Christina Bauer; Elke Ciesielski; Simon Krah; Stefan Becker; Lars Toleikis; Jonas Kügler; André Frenzel; Bernhard Valldorf; Michael Hust; Stefan Zielonka
Journal:  Mol Biotechnol       Date:  2020-04       Impact factor: 2.695

Review 3.  Peptide aptamers: development and applications.

Authors:  Sergey Reverdatto; David S Burz; Alexander Shekhtman
Journal:  Curr Top Med Chem       Date:  2015       Impact factor: 3.295

Review 4.  Therapeutic antibodies for autoimmunity and inflammation.

Authors:  Andrew C Chan; Paul J Carter
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

5.  Radiosensitization and growth inhibition of cancer cells mediated by an scFv antibody gene against DNA-PKcs in vitro and in vivo.

Authors:  Li Du; Li-Jun Zhou; Xiu-Jie Pan; Yu-Xiao Wang; Qin-Zhi Xu; Zhi-Hua Yang; Yu Wang; Xiao-Dan Liu; Mao-Xiang Zhu; Ping-Kun Zhou
Journal:  Radiat Oncol       Date:  2010-08-12       Impact factor: 3.481

6.  Therapeutic antibodies: current state and future trends--is a paradigm change coming soon?

Authors:  Dimiter S Dimitrov; James D Marks
Journal:  Methods Mol Biol       Date:  2009

7.  Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development.

Authors:  Meric Ovacik; Kedan Lin
Journal:  Clin Transl Sci       Date:  2018-08-07       Impact factor: 4.689

8.  FN3-based monobodies selective for the receptor binding domain of the SARS-CoV-2 spike protein.

Authors:  Christina J Miller; Jennifer E McGinnis; Michael J Martinez; Guangli Wang; Jian Zhou; Erica Simmons; Tohti Amet; Sanofar J Abdeen; James W Van Huysse; Ronald R Bowsher; Brian K Kay
Journal:  N Biotechnol       Date:  2021-02-05       Impact factor: 6.490

9.  Construction and analysis of high-complexity ribosome display random peptide libraries.

Authors:  Li-Min Yang; Jing-Lin Wang; Lin Kang; Shan Gao; Yan-hua Liu; Ting-Mao Hu
Journal:  PLoS One       Date:  2008-05-21       Impact factor: 3.240

Review 10.  Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies.

Authors:  Brian A Baldo
Journal:  Antibodies (Basel)       Date:  2022-02-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.